Study On 67kDaLN-R Expression In Ovarian Carcinoma And Gene Therapy On Ovarian Carcinoma By 67kDaLN-R Antisense Oligonucleiotide

Being one of the most harmful genital malignant tumors, ovarian cancer has the highest mortality rate of all gynecologic malignancies. Since the early symptoms of ovarian cancer are obscure and secretly, 60-70 % of patients present with already advanced disease, requiring major surgery and intensive and often complex additional therapies. The development of metastasis is the main cause of death of this cancer. So looking for a valuable and helpful way for biological therapy of ovarian cancer hasbeen the hot spot in the study of ovarian carcinoma.As a totally new way in biological field antisense nucleate technology has very huge potential and is getting more and more importance from the investigators. It usually means antisense oligonucleotides. To choose the target gene which has therapeutic action on tumor is the key of the antisense technology. It has been reported that 67kDa laminin receptor (67kDaLN-R) plays very important role in the invasion and metastasis of the malignant tumors. So we choose 67kDaLN-R to be the target gene to inhibit the invasion and metastasis in ovarian cancer.Three parts are presented here. The first part investigated the correlation between the expression of 67 kDa laminin receptor gene and different stage, grading, lymph node metastasis (or distant metastasis) and cancerous ascites of ovarian carcinomas. The second part was an invitro test to investigate the effects of 67kDaLN-R antisense oligodeoxynucleotides (67kDaLN-R ASODN) on biological behavior of ovarian carcinoma cell line HRA. The last part was an invivo test to observe the effects of 67kDaLN-R ASODN on the growth of the subcutaneously transplanted tumor and the growth, ascites formation and peritoneal dissemination of introperitoneally inoculated tumor in nude mice. 67kDaLN-R ASODN may be a new target for biological therapy of ovarian carcinoma.